Aim The aim of this study was to describe systematically the best available intervention
evidence for children with cerebral palsy (CP). Method This study was a systematic review of …

Botulinum neurotoxin has revolutionized the treatment of spasticity and is now administered
worldwide. There are currently three leading botulinum neurotoxin type A products available …

Non‐technical summary Muscle spasticity, due to an upper motoneuron lesion, often leads
to muscle contractures that limit range of motion and cause increased muscle stiffness …

History The therapeutic use of BT was prepared during the late 1960s by Alan B. Scott from
the Smith-Kettlewell Eye Research Institute, San Francisco, CA, USA [67]. Searching for a …

Botulinum neurotoxin type‐A (BoNT‐A) has been used in association with other
interventions in the management of spasticity in children with cerebral palsy (CP) for almost …

Rekand T. Clinical assessment and management of spasticity: a review. Acta Neurol Scand:
2010: 122 (Suppl. 190): 62–66.© 2010 John Wiley & Sons A/S. Spasticity is a sign of upper …

Dystonia may produce co‐contractions and constant strain in numerous muscle fibers,
including those of the muscle spindles. As proprioceptors, muscle spindles detect dynamic …

Botulinum neurotoxin (BoNT) is most commonly used to reduce focal over‐activity in skeletal
muscle, although newer indications such as management of drooling, pain and tremor are …

Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-
A) in the treatment of children with cerebral palsy (CP), with a special focus on the lower …

Background Improved walking is one of the highest priorities in people living with stroke.
Post-stroke lower limb spasticity (PSLLS) impedes walking and quality of life (QOL). The …